Thursday, November 15, 2012

18:00 – 19:30  DPP-4 and cardiovascular disease

Chairs: Ceriello A (Spain) Valensi P (France)

18:00  Incretin therapy and cardiovascular risk
       Marx N (Germany)

18:30  Non glycemic effects of DPP-4 inhibitors
       Avogaro A (Italy)

19:00  Myocardial graft and diabetes
       Menasché I (France)

Supported by an unrestricted grant of MSD

19:30 – 20:30  Sleep apnea syndrome and cardio-metabolic risk

Chairs: Lalic N (Serbia) Vergès B (France)

19:30  Markers of cardiovascular disease in the sleep apnea syndrome
       Mohlenkamp S (Germany)

20:00  Metabolic disorders in the sleep apnea syndrome
       Wildung J (UK)

Supported by an unrestricted grant of ResMed
Friday, November 16, 2012

08:30 – 10:35  Diabetes and coronary artery disease

   Chair:  Standl E (Germany)
           Ryden L (Sweden)

08:30  Silent myocardial ischemia in diabetes patients
       Cosson E (France)

09:00  Care of the hyperglycaemic diabetic patient during the immediate follow-up of
       acute coronary syndrome
       Vergès B (France)

09:30  Targeting normoglycemia in dysglycemia patients at high CV risks: what are
       the benefits and risks?
       Ryden L (Sweden)

10:00  OP 1: Risk predictors of cardio- and cerebrovascular hospital mortality in
       diabetic patients of the Munich Registries
       Boenner P (Germany)

10:15  OP 2: Presence of albuminuria can determine eligible subjects for the
       screening of coronary artery disease in patients with diabetes mellitus
       Sanghoon S (Korea)

10:35 – 11:00  Coffee break

11:00 – 13:00  Evaluation of cardiovascular risk

   Chair:  Avogaro A (Italy)
           Cosson E (France)

11:00  Not all fat is bad in cardiovascular risk – mechanistic considerations about
       visceral versus femoral adipose tissues
       Lafontan M (France)

11:30  A model for predicting cardiovascular risk in patients with type-2-diabetes
       mellitus based on the ADVANCE study
       Travert F (France)

11:55  What is behind the cardiovascular residual risk?
       Valensi P (France)

12:20  OP 3: Oxidized LDL as residual lipid risk marker in type-2-diabetes
       Popovic (Serbia)

12:35  OP 4: Metformin decreases plasma levels of fibulin-1, a novel marker of
       arterial matrix alterations in diabetes
       Rasmussen LM (Denmark)
Friday, November 16, 2012

12:50 OP 5: Low cardiovascular (CV) risk hazard ratio observed with linagliptin in type-2-diabetes: further insights from a predefined CV meta-analysis
Johansen OE (Germany, USA, UK)

13:00 – 14:00 Lunch

14:00 – 15:00 Poster Sessions 1 and 2

Poster Session 1 (P1-P8)
Atherosclerosis, peripheral and cerebrovascular disease
Chair: Roussel R (France)

Poster Session 2 (P9-P16)
Oxidative stress and endothelium dysfunction
Chair: Boutouyrié P (France)

15:00 – 16:30 Dietary factors and cardiovascular complications

Chair: Avignon A (France)
Schalkwijk C (Netherlands)

15:00 Role of postprandial hyperglycemia and glycemic variability
Ceriello A (Spain)

15:25 Advanced glycation endproducts in food and medicine
Schalkwijk C (Netherlands)

15:50 Exercise, sympatho-vagal balance and postprandial glucose profile
Chapelot D (France)

16:15 OP6: Endothelium-independent vascular reactivity in high-fat diet-fed rats: role of vascular wall and perivascular adipose tissue oxidative stress
Achard V (France)

16:30 – 16:45 Coffee break

16:45 – 18:35 Vascular impairment in diabetes

Chair: Levy B (France)
Natali A (Italy)

16:45 Functional and morphological changes in the arterial wall in diabetes and during aging: Role of AGE
Grossin N (France)
Friday, November 16, 2012

17:05  Endothelial dysfunction in diabetes
       Natali A (Italy)

17:30  Microvascular rarefaction in diabetes and hypertension
       Levy B (France)

18:00  Artery stiffness and remodelling in diabetes and renal failure
       Boutouyrié P (France)

18:20  OP 7: Chronic hyperglycemia induces GLP-1R resistance in terms of
       antioxidant and ER stress response in HuVEC cells
       Pujadas G (Spain)

18:35  OP 8: Early atherosclerosis in Familial Partial Lipodystrophy of the
       Dunnigan-type: endothelial cell dysfunction induced by p.R482W
       lamin-A
       Bidault G (France)

Supported by an unrestricted grant of Novartis

18:50  General Assembly
Saturday, November 17, 2012

08:30 – 10:30  Coronary revascularization and peripheral vascular disease

Chair:  Bonnet F (France)
        Moulin P (France)

08:30  Impaired glucose tolerance and cardiovascular risk  
       Schnell O (Germany)

09:00  Should we still revascularize with coronary patients and how?  
       Varenne O (France)

09:30  Which antiaggregant strategy in diabetic patients with coronary artery disease  
       Gilard M (France)

10:00  Metabolic determinants of cerebrovascular disease in type 2 diabetes  
       Lalic N (Serbia)

Supported by an unrestricted grant of Abbott

10:30 – 11:00  Coffee break

11:00 – 12:30  Antiplatelet and antithrombotic therapy in diabetes

Chair:  Gilard M (France)
        Bonnet F (France)

11:00  Aspirin efficacy in diabetes  
       Drouet L (France)

11:30  New oral anticoagulants  
       Apostolakis S (UK)

12:00  OP 10: Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status  
       Sanchez C (France)

12:30  OP 11: Analysis of the relationship between the presence of metabolic syndrome with the level of oxidized LDL and impaired fibrinolysis in patients with type 2 diabetes  
       Singh A (Serbia)

Supported by an unrestricted grant of Boehringer Ingelheim
Saturday, November 19, 2012

12:30 – 13:30  Lunch

13:00 – 14:30  Poster Sessions 3 and 4

Poster Session 3 (P17-P24)
Coronary artery disease and heart dysfunction
Chair: Jelic S (Serbia)

Poster Session 4 (P25-P31)
New pathways, new treatments, new strategies
Chair: Catargi B (France)

14:30 – 16:30  Myocardial dysfunction in diabetes and aberrations of myocardial metabolism

Chair: Giorda C (Italy)
Grynberg A (France)

14:30  Early left ventricular dysfunction in diabetes
Giorda C (Italy)

14:55  How molecular imaging may guide personalized cardiovascular risk assessment and care?
Rouzet F (France)

15:20  Omega 3 PUFA chain length: a key factor of their efficiency on cardiovascular risk factors in experimental metabolic syndrome
Grynberg A (France)

15:45  OP12: Metabolic and cardiovascular determinants of increased left ventricular torsion in patients with type 2 diabetes mellitus
Kuehl M (UK)

16:00  OP 13: Association between retinopathy and early echographic markers of cardiomyopathy in type 2 diabetes
Decker-Bellaton A (France)

16:15  OP 14: The effect of poly ADP-ribosepolymerase inhibitors on diabetic-induced heart dysfunctions
Kuchmerovska T (Ukraine)

16:30  Closing of the meeting